Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients

The EANM Journal · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles